<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02785601</url>
  </required_header>
  <id_info>
    <org_study_id>Zhaoke-201603-Tra-Trial I</org_study_id>
    <nct_id>NCT02785601</nct_id>
  </id_info>
  <brief_title>PK Study of Diet Effect of Trazodone Hydrochloride Prolonged-Released Tablets in Healthy Chinese</brief_title>
  <official_title>Pharmacokinetics Study of Trazodone Hydrochloride Prolonged -Released Tablets in Chinese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to compare the pharmacokinetics in single dose, and effect of food on&#xD;
      the trazodone hydrochloride pharmacokinetics prolonged-release tablets.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial I single dose (75mg and 150mg), fasting or postprandial comparative pharmacokinetics of&#xD;
      trazodone hydrochloride prolonged-release tablets and ordinary formulation; 16 patients&#xD;
      (males and females, half and half).&#xD;
&#xD;
      Trial is a 4-period, 4 cross (4x4) Williams crossover design, screened 16 subjects (half&#xD;
      males and half females) were randomly divided into four groups (I-1, I-2, I-3, I-4), each 2&#xD;
      men and 2 women, give the following four different crossover treatments:&#xD;
&#xD;
      (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg;&#xD;
      (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150&#xD;
      mg; (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg;&#xD;
      (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) Time&#xD;
      for drug administration is around 8:00am. Wash-out period is 7 days. Blood sampling will be&#xD;
      performed before (0h) and after administration each dose group 0.5, 1.0, 2.0, 3.0, 4.0, 5.0,&#xD;
      6.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0, 72.0h.&#xD;
&#xD;
      Trial I. 4X4 Williams design Group Period 1 Period 2 Period 3 Period 4 I-1 A D B C I-2 B A C&#xD;
      D I-3 C B D A I-4 D C A B&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Actual">January 4, 2018</completion_date>
  <primary_completion_date type="Actual">November 30, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>pre-dose, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 16 hours, 24 hours, 36 hours, 48 hours, 72 hours after administration</time_frame>
    <description>To observe area under curve characteristics of trazodone hydrochloride prolonged-release tablets in single or multiple dose groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>pre-dose, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 16 hours, 24 hours, 36 hours, 48 hours, 72 hours after administration</time_frame>
    <description>To observe area under curve characteristics of trazodone hydrochloride prolonged-release tablets in fasting or high-fat diet groups</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>I-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>I-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>I-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>I-4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone Hydrochloride prolonged-release tablets</intervention_name>
    <description>strength 75mg, 150 mg. Oral administration with 200ml water</description>
    <arm_group_label>I-1</arm_group_label>
    <arm_group_label>I-2</arm_group_label>
    <arm_group_label>I-3</arm_group_label>
    <arm_group_label>I-4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Weight: all the subjects should be ≥50 kg, BMI within 19~24 kg/m2；&#xD;
&#xD;
          -  Blood pressure: SBP 90-140mmHg，DBP 50-90 mmHg；&#xD;
&#xD;
          -  All the subjects should understand this trial well and sign the inform consent form&#xD;
             before participating this study;&#xD;
&#xD;
          -  Subjects should be able to communicate with investigators well and complete this study&#xD;
             in accordance with protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The baseline value of safety evaluation index is considered to be abnormal with&#xD;
             clinical significance by investigators before participating the trial.&#xD;
&#xD;
          -  A positive hepatitis B surface antigen result；&#xD;
&#xD;
          -  A positive hepatitis C surface antigen result；&#xD;
&#xD;
          -  A positive test for HIV antibody and syphilis testing；&#xD;
&#xD;
        Any of the abnormalities of ECGs examination occurs in screening period or the first day of&#xD;
        administration:&#xD;
&#xD;
          -  With the history of using any drug which will inhibit or induce liver to metabolize&#xD;
             drug within 1 month before the study initiation;&#xD;
&#xD;
          -  With the history of administrating any drugs (prescription medicine, over-the-counter&#xD;
             drug and Chinese herbal medicine) within 2 week before the study initiation;&#xD;
&#xD;
          -  Past history of heart disease, cardiac failure, myocardial infarction, angina, unknown&#xD;
             cause of arrhythmia, point swinging pattern of ventricular tachycardia, ventricular&#xD;
             tachycardia, long QT syndrome or long QT syndrome and family history (with genetic&#xD;
             proof or there were any close relatives died because of heart disease);&#xD;
&#xD;
          -  History of thyroid disease or past history of thyroid surgery;&#xD;
&#xD;
          -  History of immune system disease (such as thymus disease)；&#xD;
&#xD;
          -  With surgery history within 6 months before this study initiation；&#xD;
&#xD;
          -  History of severe digestive disease (such as gallbladder disease with significant&#xD;
             clinical significance, jaundice or susceptive jaundice, hepatocellular adenoma,&#xD;
             hepatic cavernous hemangioma and the other liver diseases)；&#xD;
&#xD;
          -  With history of gastrointestinal, liver and renal disease (no matter it has been cured&#xD;
             or not) which will affect drug absorption and metabolism within 6 months before this&#xD;
             study initiating；&#xD;
&#xD;
          -  History of any serve cardiocerebral vascular system, respiratory system, metabolic&#xD;
             system and nervous system diseases;&#xD;
&#xD;
          -  History of hematological system diseases, such as coagulation disorders；&#xD;
&#xD;
          -  History of tumor；&#xD;
&#xD;
          -  Subjects with hypokalemia and hypocalcemia (according to the lower limit value of the&#xD;
             laboratory reference ranges；&#xD;
&#xD;
        Life style:&#xD;
&#xD;
          -  History of alcohol addicted within 6 months before the study&#xD;
&#xD;
          -  Smoking &gt;1 cigarettes a day in the last 3 months prior to this study;&#xD;
&#xD;
          -  History of drug abuse and taking drugs (such as marihuana, cocaine, opium,&#xD;
             benzodizepines, amphetamines, barbiturates, tricyclic antidepressant).&#xD;
&#xD;
          -  History of consumption of excessive tea, coffee and/or caffeinated beverage (more than&#xD;
             8 cups/day) within the period of 2 days before the administration and 8 days after&#xD;
             administration.&#xD;
&#xD;
          -  History of consumption of grapefruit juice within the period of 2 days before and 8&#xD;
             days after administration.&#xD;
&#xD;
        Others：&#xD;
&#xD;
          -  Subjects who reject to take effective contraceptive measures within the time period&#xD;
             after inclusion to 3 months after administration;&#xD;
&#xD;
          -  Subjects with allergic constitution, including those who are allergic to the excipient&#xD;
             (microcrystalline cellulose, lactose, aerosil, sodium carboxymethyl starch, magnesium&#xD;
             stearate) of this product;&#xD;
&#xD;
          -  History of participating any clinical trial within 3 months before this study, or&#xD;
             participating the other clinical trial within the time period of inclusion to one&#xD;
             month after the last time visit(after the last time administration);&#xD;
&#xD;
          -  History of blood donation within 3 months prior to this study, or within the time&#xD;
             period of inclusion to one month after the last time visit (after the last time&#xD;
             administration);&#xD;
&#xD;
          -  Subjects who have food allergy or have any special diet requirements, or who cannot&#xD;
             follow the standard diet;&#xD;
&#xD;
          -  Subjects who, in the opinion of the investigator, should not participate in the study.&#xD;
&#xD;
        The female subjects are not eligible for inclusion in this study if she meet any of the&#xD;
        following criteria above and below:&#xD;
&#xD;
          -  With the history of consumption of oral contraceptive within one month prior to this&#xD;
             study；&#xD;
&#xD;
          -  History of long-acting estrogen or progesterone injection or implant within 6 months&#xD;
             prior to this study;&#xD;
&#xD;
          -  The bearing-age female subjects who have not taken appropriate contraceptives within 2&#xD;
             weeks prior to this study;&#xD;
&#xD;
          -  The bearing-age female subjects and their spouse are not willing to take the following&#xD;
             contraceptives measure, condom, copper intrauterine device within 3 months after&#xD;
             inclusion;&#xD;
&#xD;
          -  Subjects who are in gestation period and lactation period;&#xD;
&#xD;
          -  Subjects with positive hCG test;&#xD;
&#xD;
          -  Single menstrual more than 80ml.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea On Yan Luk</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prince of Wales Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2016</study_first_posted>
  <last_update_submitted>September 2, 2018</last_update_submitted>
  <last_update_submitted_qc>September 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trazodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

